The average one-year price target for Acumen Pharmaceuticals (NasdaqGS:ABOS) has been revised to 13.06 / share. This is an increase of 6.67% from the prior estimate of 12.24 dated March 28 ...

Taylor Swift's successes and failures, including the battle to regain control of her master recordings, are part of the ...

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted ...

Ridley Sr., PhD., RTTP receives the Frederick J. Beste III Partnership Award at the Ben Franklin Technology Partners of ...

The integration of artificial intelligence into various facets of business operations has not only streamlined processes but also introduced complexities that demand a higher level of business ...

Acumen Pharmaceuticals signed a collaboration agreement with Lonza that covers the manufacture of sabirnetug (ACU193), an antibody targeting toxic soluble amyloid beta oligomers (AβOs ...

Sabirnetug is under clinical development by Acumen Pharmaceuticals and currently in Phase I for Dementia Associated With Alzheimer's Disease.

Ahead of their highly anticipated main event clash at UFC 303, Michael Chandler offers recognition to Conor McGregor for his ...

Army Lt. Gen. Mark Simerly, director of the Defense Logistics Agency, highlighted the importance of data within DLA and the ...

One stock that might be an intriguing choice for investors right now is Acumen Pharmaceuticals, Inc. ABOS. This is because this security in the Medical - Biomedical and Genetics space is seeing ...